Peter Marklund's Home

A pharma company without sales - according to John Wilkerson of Galen Associates, a health-care investment company in New York.

About a month ago the Economist featured a survey on Biotechnology. As any Economist survey it was quite well written and interesting. The articles covered the investment drain of the industry, controversial concepts such as cloning (which hasn't shown too promising signs yet), improvements to medicine and agriculture, the danger of biotech weapons and much more.

Also featured was a Biotech Industry "Cluster Analysis". It identified San Diego as an up-and-coming hot-spot (promoted as Biotech Beach), alongside concentrations in the San Francisco Bay area, Boston, Cambridge UK, and, as I was very proud to note, Uppsala in Sweden...